ItalyItaly

Philogen cancels IPO after Bayer terminates partnership

16.02.2011

Milan/Berlin – Swiss-Italian biotech Philogen SpA has revoked its plan to sell a 23% stake worth EUR65.3m and go public on the Milan stock exchange this Friday. The move came after German Bayer HealthCare unexpectedly terminated an exclusive licence agreement with Philogen involving the firm’s immunocytokine darleukin (L19-IL2). At the time of Bayer’s announcement, the dimeric fusion protein of a fully human scFv which targets the Fibronectin EBD domain which almost exclusively occurs in tumour vasculature and the proinflammatory cytokine IL-2, was tested in two Phase II studies in malignant melanoma. In both, a primary endpoint was objective response rate. A spokesman for Bayer confirmed that it had informed Philogen about its decision to terminate the licensing agreement, but he declined to give any further details.

ItalyItaly

04.11.2010

Rome/Milan – Together with two Italian research institutes, British drug giant Glaxo­SmithKline has begun to develop a therapy for the heriditary immune defect ADA-SCID, which affects only 350 children worldwide. Fondazione...

ItalyItaly

03.11.2010

Rome – When it comes to GMOs, the gap between Italy’s federal government and its regions that has marked the country for years is rapidly widening into a gulf. The latest rupture was on display at the October session of the...

ItalyItaly

18.09.2010

Valletta – A new Life Sciences Park is to be created on the outskirts of Malta’s capital Valletta. The EUR20m project will provide space for companies operating in biotechnology and medical sciences. The park will be located in...

ItalyItaly

17.09.2010

Verona – Scientists at Glaxo­SmithKline in Verona have discovered that specific neurons in the amygdala control how mice react to fear stimuli. When they switched off the so-called Type I cells in the animals’ amyg­dala, the mice...

ItalyItaly

29.08.2010

San Michele all’Adige – The genetic code of the Golden Delicious apple has been deciphered. Led by Riccardo Velasco at the Edmund Mach Foundation in San Michele all’Adige in Italy’s Trentino province, a team of scientists from 20...

ItalyItaly

12.07.2010

: It’s hard to be a pro-GMO campaigner in Italy. Since 2001, the regions there have not implemented the plans for coexistence that were suggested by a ministerial decree. Instead, there was a de facto Italian moratorium on GM...

ItalyItaly

10.07.2010

Milan – One of Italy’s biggest biotech players wants to raise EUR58m to boost its pipeline of cancer therapies. The round will be closed on July 16th. With operating costs of EUR22.5m and a total loss of about EUR17m in 2009,...

ItalyItaly

10.07.2010

Milan – Italian researchers have restored sight to blind patients using stem cells from the patients’ own bodies. In a study published by the New England Journal of Medicine (10.1056/NEJMoa0905955), scientists from Modena and...

ItalyItaly

13.05.2010

Rome/Maryland – The Vatican has taken a bold step into unchartered territory with its decision to finance new research into the potential use of adult stem cells for the treatment of intestinal disease and possibly other...

Displaying results 21 to 30 out of 181

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-italy/browse/2/article/philogen-cancels-ipo-after-bayer-terminates-partnership.html

Events

All Events

Stock list

All quotes

TOP

  • SANTHERA98.35 CHF13.70%
  • EPIGENOMICS3.37 EUR6.65%
  • FORMYCON6.85 EUR1.48%

FLOP

  • MOLOGEN7.38 EUR-5.87%
  • EVOTEC3.74 EUR-5.08%
  • CYTOS0.25 CHF-3.85%

TOP

  • SANTHERA98.35 CHF53.7%
  • BB BIOTECH141.00 EUR6.3%
  • ADDEX3.98 CHF4.2%

FLOP

  • WILEX2.25 EUR-24.7%
  • MOLOGEN7.38 EUR-18.8%
  • 4SC1.22 EUR-15.9%

TOP

  • SANTHERA98.35 CHF4121.0%
  • CO.DON2.48 EUR210.0%
  • PAION2.43 EUR179.3%

FLOP

  • CYTOS0.25 CHF-93.6%
  • MEDIGENE4.55 EUR-67.9%
  • THERAMETRICS0.08 CHF-42.9%

No liability assumed, Date: 28.08.2014


Current issue

All issues

Product of the week

Products